Hepatic tyrosine aminotransferase inhibitor affects the bioavailability of exogenous tyrosine.
This study demonstrates the importance of controlling the activity of hepatic tyrosine aminotransferase when tyrosine is administered orally. The specific inhibition of this enzyme is proposed in the clinical use of tyrosine in syndromes related to deficient catecholaminergic transmission.
D000818:Animals; D001682:Biological Availability; D001923:Brain Chemistry / Q000187:drug effects; D005990:Glycerol / Q000494:pharmacology; D007700:Kinetics; D008099:Liver / Q000201:enzymology* / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D014443:Tyrosine / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D014444:Tyrosine Transaminase / Q000037:antagonists & inhibitors*
D014443:Tyrosine; D014444:Tyrosine Transaminase; D005990:Glycerol